Johan L. K. Van Hove
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johan L. K. Van Hove has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Curtis R. Coughlin
Section of Clinical Genetics and Metabolism, Department of Pediatrics University of Colorado Anschutz Medical Campus Aurora Colorado USA
5 shared publications Marisa W. Friederich
Section of Clinical Genetics and Metabolism, Department of Pediatrics, University of Colorado, Aurora, 80045, CO, USA
5 shared publicationsMichael A. Swanson
Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado, 13121 East 17th Avenue, Aurora, CO 80045, USA
4 shared publicationsElaine B. Spector
Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado School of Medicine, Aurora, CO 80045, USA
3 shared publicationsKathryn C. Chatfield
Department of Pediatrics, Section of Pediatric Cardiology, Children’s Hospital Colorado, University of Colorado, Aurora, CO, 80045, USA
3 shared publicationsEric Wartchow
Department of Pathology, Children’s Hospital Colorado, University of Colorado, Aurora, 80045, CO, USA
2 shared publications
Latest Publications
- Open Access
- 3 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 4065
Pathogenic variants in glutamyl-tRNAGln amidotransferase subunits cause a lethal mitochondrial cardiomyopathy disorder
Mitochondrial protein synthesis requires charging mt-tRNAs with their cognate amino acids by mitochondrial aminoacyl-tRNA synthetases, with the exception of glutaminyl mt-tRNA (mt-tRNAGln). mt-tRNAGln is indirectly charged by a transamidation reaction involving the GatCAB aminoacyl-tRNA amidotransferase complex. Defects involving the mitochondrial protein synthesis machinery cause a broad spectrum of disorders, with often fatal outcome. Here, we describe nine patients from five families with genetic defects in a GatCAB complex subunit, including QRSL1, GATB, and GATC, each showing a lethal metabolic cardiomyopathy syndrome. Functional studies reveal combined respiratory chain enzyme deficiencies and mitochondrial dysfunction. Aminoacylation of mt-tRNAGln and mitochondrial protein translation are deficient in patients’ fibroblasts cultured in the absence of glutamine but restore in high glutamine. Lentiviral rescue experiments and modeling in S. cerevisiae homologs confirm pathogenicity. Our study completes a decade of investigations on mitochondrial aminoacylation disorders, starting with DARS2 and ending with the GatCAB complex.
- 3 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 4065
Open AccessPathogenic variants in glutamyl-tRNAGln amidotransferase subunits cause a lethal mitochondrial cardiomyopathy disorder
Mitochondrial protein synthesis requires charging mt-tRNAs with their cognate amino acids by mitochondrial aminoacyl-tRNA synthetases, with the exception of glutaminyl mt-tRNA (mt-tRNAGln). mt-tRNAGln is indirectly charged by a transamidation reaction involving the GatCAB aminoacyl-tRNA amidotransferase complex. Defects involving the mitochondrial protein synthesis machinery cause a broad spectrum of disorders, with often fatal outcome. Here, we describe nine patients from five families with genetic defects in a GatCAB complex subunit, including QRSL1, GATB, and GATC, each showing a lethal metabolic cardiomyopathy syndrome. Functional studies reveal combined respiratory chain enzyme deficiencies and mitochondrial dysfunction. Aminoacylation of mt-tRNAGln and mitochondrial protein translation are deficient in patients’ fibroblasts cultured in the absence of glutamine but restore in high glutamine. Lentiviral rescue experiments and modeling in S. cerevisiae homologs confirm pathogenicity. Our study completes a decade of investigations on mitochondrial aminoacylation disorders, starting with DARS2 and ending with the GatCAB complex.
- 26 September 2018
- Published by Springer Publishing Company
Glycine Encephalopathy and Epilepsy
The glycine encephalopathies are a group of genetic disorders causing neurological dysfunction, and are characterized by disturbances of brain glycine transport and metabolism. Nonketotic hyperglycinemia (NKH) is an autosomal recessive inborn error of glycine degradation leading to severe neurological symptoms with intractable seizures and brain abnormalities. NKH is caused by a deficiency of the glycine cleavage system, resulting in an excessive accumulation of glycine in all tissues and biological fluids, particularly in the central nervous system. Seizures occur in all forms of NKH, but they remain persistent and intractable only in patients with severe classic NKH. This chapter gives an overview of the occurrence of seizures in the different NKH forms. Current therapy for classic NKH is directed at decreasing glycine concentrations and blocking the effect of glycine at the neurotransmitter receptors. Benzoate treatment and a low-protein diet can effectively reduce glycine concentrations in plasma and consecutively in cerebrospinal fluid.
- 26 September 2018
- Published by Springer Publishing Company
Glycine Encephalopathy and Epilepsy
The glycine encephalopathies are a group of genetic disorders causing neurological dysfunction, and are characterized by disturbances of brain glycine transport and metabolism. Nonketotic hyperglycinemia (NKH) is an autosomal recessive inborn error of glycine degradation leading to severe neurological symptoms with intractable seizures and brain abnormalities. NKH is caused by a deficiency of the glycine cleavage system, resulting in an excessive accumulation of glycine in all tissues and biological fluids, particularly in the central nervous system. Seizures occur in all forms of NKH, but they remain persistent and intractable only in patients with severe classic NKH. This chapter gives an overview of the occurrence of seizures in the different NKH forms. Current therapy for classic NKH is directed at decreasing glycine concentrations and blocking the effect of glycine at the neurotransmitter receptors. Benzoate treatment and a low-protein diet can effectively reduce glycine concentrations in plasma and consecutively in cerebrospinal fluid.
- 7 May 2018
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (4) , 751
In memoriam
- 26 September 2017
- Published by Elsevier in Pediatric Neurology
- Vol. 79, e1
Comment on Late-Onset Nonketotic Hyperglycinemia With a Heterozygous Novel Point Mutation of the GLDC Gene
- 26 September 2017
- Published by Elsevier in Pediatric Neurology
- Vol. 79, e1
Comment on Late-Onset Nonketotic Hyperglycinemia With a Heterozygous Novel Point Mutation of the GLDC Gene
- 1 June 2017
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 121 (2) , 80-82
d-Glyceric aciduria does not cause nonketotic hyperglycinemia: A historic co-occurrence
- 1 June 2017
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 121 (2) , 80-82
d-Glyceric aciduria does not cause nonketotic hyperglycinemia: A historic co-occurrence
- Open Access
- 30 December 2016
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 26 (4) , 702-716
Mutations in the accessory subunitNDUFB10result in isolated complex I deficiency and illustrate the critical role of intermembrane space import for complex I holoenzyme assembly
An infant presented with fatal infantile lactic acidosis and cardiomyopathy, and was found to have profoundly decreased activity of respiratory chain complex I in muscle, heart and liver. Exome sequencing revealed compound heterozygous mutations in NDUFB10, which encodes an accessory subunit located within the PD part of complex I. One mutation resulted in a premature stop codon and absent protein, while the second mutation replaced the highly conserved cysteine 107 with a serine residue. Protein expression of NDUFB10 was decreased in muscle and heart, and less so in the liver and fibroblasts, resulting in the perturbed assembly of the holoenzyme at the 830 kDa stage. NDUFB10 was identified together with three other complex I subunits as a substrate of the intermembrane space oxidoreductase CHCHD4 (also known as Mia40). We found that during its mitochondrial import and maturation NDUFB10 transiently interacts with CHCHD4 and acquires disulfide bonds. The mutation of cysteine residue 107 in NDUFB10 impaired oxidation and efficient mitochondrial accumulation of the protein and resulted in degradation of non-imported precursors. Our findings indicate that mutations in NDUFB10 are a novel cause of complex I deficiency associated with a late stage assembly defect and emphasize the role of intermembrane space proteins for the efficient assembly of complex I.
- 30 December 2016
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 26 (4) , 702-716
Open AccessMutations in the accessory subunitNDUFB10result in isolated complex I deficiency and illustrate the critical role of intermembrane space import for complex I holoenzyme assembly
An infant presented with fatal infantile lactic acidosis and cardiomyopathy, and was found to have profoundly decreased activity of respiratory chain complex I in muscle, heart and liver. Exome sequencing revealed compound heterozygous mutations in NDUFB10, which encodes an accessory subunit located within the PD part of complex I. One mutation resulted in a premature stop codon and absent protein, while the second mutation replaced the highly conserved cysteine 107 with a serine residue. Protein expression of NDUFB10 was decreased in muscle and heart, and less so in the liver and fibroblasts, resulting in the perturbed assembly of the holoenzyme at the 830 kDa stage. NDUFB10 was identified together with three other complex I subunits as a substrate of the intermembrane space oxidoreductase CHCHD4 (also known as Mia40). We found that during its mitochondrial import and maturation NDUFB10 transiently interacts with CHCHD4 and acquires disulfide bonds. The mutation of cysteine residue 107 in NDUFB10 impaired oxidation and efficient mitochondrial accumulation of the protein and resulted in degradation of non-imported precursors. Our findings indicate that mutations in NDUFB10 are a novel cause of complex I deficiency associated with a late stage assembly defect and emphasize the role of intermembrane space proteins for the efficient assembly of complex I.
- Open Access
- 1 March 2016
- Published by Elsevier in The Journal of Pediatrics
- Vol. 170, 234-239
Neurodevelopmental Outcome and Treatment Efficacy of Benzoate and Dextromethorphan in Siblings with Attenuated Nonketotic Hyperglycinemia
- 1 March 2016
- Published by Elsevier in The Journal of Pediatrics
- Vol. 170, 234-239
Open AccessNeurodevelopmental Outcome and Treatment Efficacy of Benzoate and Dextromethorphan in Siblings with Attenuated Nonketotic Hyperglycinemia
- 1 March 2015
- Published by Elsevier in Mitochondrion
- Vol. 21, 1-10
Mitochondrial energy failure in HSD10 disease is due to defective mtDNA transcript processing
- 1 March 2015
- Published by Elsevier in Mitochondrion
- Vol. 21, 1-10
Mitochondrial energy failure in HSD10 disease is due to defective mtDNA transcript processing
- Open Access
- 1 January 2014
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 1, 237-240
Concurrent non-ketotic hyperglycinemia and propionic acidemia in an eight year old boy
- 1 January 2014
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 1, 237-240
Open AccessConcurrent non-ketotic hyperglycinemia and propionic acidemia in an eight year old boy
- Open Access
- 10 December 2013
- Published by Oxford University Press (OUP) in Brain
- Vol. 137 (2) , 366-379
Variant non ketotic hyperglycinemia is caused by mutations in LIAS, BOLA3 and the novel gene GLRX5
Patients with nonketotic hyperglycinemia and deficient glycine cleavage enzyme activity, but without mutations in AMT, GLDC or GCSH, the genes encoding its constituent proteins, constitute a clinical group which we call ‘variant nonketotic hyperglycinemia’. We hypothesize that in some patients the aetiology involves genetic mutations that result in a deficiency of the cofactor lipoate, and sequenced genes involved in lipoate synthesis and iron-sulphur cluster biogenesis. Of 11 individuals identified with variant nonketotic hyperglycinemia, we were able to determine the genetic aetiology in eight patients and delineate the clinical and biochemical phenotypes. Mutations were identified in the genes for lipoate synthase (LIAS), BolA type 3 (BOLA3), and a novel gene glutaredoxin 5 (GLRX5). Patients with GLRX5-associated variant nonketotic hyperglycinemia had normal development with childhood-onset spastic paraplegia, spinal lesion, and optic atrophy. Clinical features of BOLA3-associated variant nonketotic hyperglycinemia include severe neurodegeneration after a period of normal development. Additional features include leukodystrophy, cardiomyopathy and optic atrophy. Patients with lipoate synthase-deficient variant nonketotic hyperglycinemia varied in severity from mild static encephalopathy to Leigh disease and cortical involvement. All patients had high serum and borderline elevated cerebrospinal fluid glycine and cerebrospinal fluid:plasma glycine ratio, and deficient glycine cleavage enzyme activity. They had low pyruvate dehydrogenase enzyme activity but most did not have lactic acidosis. Patients were deficient in lipoylation of mitochondrial proteins. There were minimal and inconsistent changes in cellular iron handling, and respiratory chain activity was unaffected. Identified mutations were phylogenetically conserved, and transfection with native genes corrected the biochemical deficiency proving pathogenicity. Treatments of cells with lipoate and with mitochondrially-targeted lipoate were unsuccessful at correcting the deficiency. The recognition of variant nonketotic hyperglycinemia is important for physicians evaluating patients with abnormalities in glycine as this will affect the genetic causation and genetic counselling, and provide prognostic information on the expected phenotypic course.
- 10 December 2013
- Published by Oxford University Press (OUP) in Brain
- Vol. 137 (2) , 366-379
Open AccessVariant non ketotic hyperglycinemia is caused by mutations in LIAS, BOLA3 and the novel gene GLRX5
Patients with nonketotic hyperglycinemia and deficient glycine cleavage enzyme activity, but without mutations in AMT, GLDC or GCSH, the genes encoding its constituent proteins, constitute a clinical group which we call ‘variant nonketotic hyperglycinemia’. We hypothesize that in some patients the aetiology involves genetic mutations that result in a deficiency of the cofactor lipoate, and sequenced genes involved in lipoate synthesis and iron-sulphur cluster biogenesis. Of 11 individuals identified with variant nonketotic hyperglycinemia, we were able to determine the genetic aetiology in eight patients and delineate the clinical and biochemical phenotypes. Mutations were identified in the genes for lipoate synthase (LIAS), BolA type 3 (BOLA3), and a novel gene glutaredoxin 5 (GLRX5). Patients with GLRX5-associated variant nonketotic hyperglycinemia had normal development with childhood-onset spastic paraplegia, spinal lesion, and optic atrophy. Clinical features of BOLA3-associated variant nonketotic hyperglycinemia include severe neurodegeneration after a period of normal development. Additional features include leukodystrophy, cardiomyopathy and optic atrophy. Patients with lipoate synthase-deficient variant nonketotic hyperglycinemia varied in severity from mild static encephalopathy to Leigh disease and cortical involvement. All patients had high serum and borderline elevated cerebrospinal fluid glycine and cerebrospinal fluid:plasma glycine ratio, and deficient glycine cleavage enzyme activity. They had low pyruvate dehydrogenase enzyme activity but most did not have lactic acidosis. Patients were deficient in lipoylation of mitochondrial proteins. There were minimal and inconsistent changes in cellular iron handling, and respiratory chain activity was unaffected. Identified mutations were phylogenetically conserved, and transfection with native genes corrected the biochemical deficiency proving pathogenicity. Treatments of cells with lipoate and with mitochondrially-targeted lipoate were unsuccessful at correcting the deficiency. The recognition of variant nonketotic hyperglycinemia is important for physicians evaluating patients with abnormalities in glycine as this will affect the genetic causation and genetic counselling, and provide prognostic information on the expected phenotypic course.